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Abstract
Background. The optimal drug dosing in anuric
patients undergoing continuous haemofiltration is a
difficult task. More pharmacokinetic data is needed to
derive practical guidelines for dosage adjustments.
Methods. Drug elimination of various antimicrobial
agents (amikacin, amoxycillin, ceftazidime, ciproflox-
acin, flucloxacillin, imipenem, netilmicin, penicillin G,
piperacillin, sulphamethoxazole, tobramycin, vanco-
mycin) was studied in 24 patients with acute renal
failure treated by pump-assisted continuous venoven-
ous haemofiltration (CVVH). Concentrations of serial
blood and ultrafiltrate samples were determined by
HPLC or by fluorescence polarization immunoassay.
Total body clearance (CL) and haemofilter clearance
(CLf) rates were determined by standard model-
independent equations. Data from published literature
on fractions not bound to proteins (fu), non-renal drug
clearance fractions (Qo), and normal clearance values(CLn) were used to derive a pharmacokinetic model,
taking into account drug removal by ultrafiltration
and by non-renal clearance.
Results. A total of 37 treatment periods was studied.
Blood flow through the haemofilters was lOOml/min
resulting in an average ultrafiltrate flow rate (UFR)
of 13.2 + 4.6 (range 3.2-22.1) ml/min. Acceptable cor-
relations of calculated and measured haemofilter clear-
ances and total body clearances were obtained.
Conclusions. Total body clearance in anuric patients
during CVVH is predictable from drug properties,
which are generally known. The individual dosage
requirements may be calculated by multiplying
Qo + fu' UFR/CLn with the dose considered appro-
priate in the absence of renal impairment.
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continuous venovenous haemofiltration; drug dosage;
pharmacokinetics
Correspondence and offprint requests to: Dr Beda Joos, Division of
Infectious Diseases, Department of Medicine, University Hospital
Zurich, CH-8091 Zurich, Switzerland.
Introduction
Continuous haemofiltration is a well-established tool
in the treatment of patients with renal failure. However,
despite good control of uraemia, acute renal failure
is often associated with a high mortality rate [1].
Septicaemia frequently complicates the disease progres-
sion, and it has been identified as a major predictor of
a poor outcome. Optimal drug dosing is thus essential
in this situation but pharmacokinetic data during con-
tinuous renal replacement therapy are scarce. Complex
mathematical models have been proposed [2,3], but
their application in clinical practice is limited. The
current methods to estimate drug removal through the
haemofilter rely on sieving coefficients, i.e. average
filtrate to blood concentration ratios [2-5]. These
values, however, must be determined previously for
each drug.
The aim of this study is to investigate the pharmaco-
kinetics of various antimicrobial agents in patients
with acute renal failure undergoing pump-assisted con-
tinuous venovenous haemofiltration (CVVH) and to
derive practical guidelines for dosage adjustments.
Subjects and methods
Selection of patients
Anuric patients undergoing continuous renal replacement
therapy and receiving antimicrobial chemotherapy were con-
sidered eligible for inclusion in the study. Drug clearance
rates were measured during the CWH in a total of 24
patients with acute renal failure due to various causes.
Haemofiltration
Pump-assisted CWH was performed by a double-lumen
subclavian catheter [1]. Blood flow through the polyamide
hollow-fibre membrane filters (Gambro FH66) was set at
100 ml/min. The replacement fluid (Ringer's lactate) was
administered in pre-dilution or post-dilution mode. The
ultrafiltrate flow rate (UFR) was continuously monitored
throughout treatment.
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Table 1. Dosage and median pharmacokinetic parameters observed in 24 patients during continuous venovenous haemofUtration
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Drug
Amikacin
Amoxycillin
Ceftazidime
Ciprofloxacin
Flucloxacillin
Imipenem
Netilmicin
Penicillin-G
Piperacillin
Sulphamethoxazole
Tobramycin
Vancomycin
Total, range
Number of
patients
2
3
6
2
3
1
6
1
8
V
1
3
37b
Number of
intervals
2
3
13
3
6
2
10
2
16
1
2
4
64
Dose
(mg)
600-800
600-1200
500-1000
200
1000-2000
500
40-200
1198
1000-4000
400
40
500-1000
40-4000
Interval
(h)
24
6-12
6-13
6-12
4-39
12
24-72
4
4-12
12
24
24-43
4-72
Half-life
(h)
15.6
5.8
13.2
7.5
9.9
3.0
13.9
12.6
10.6
9.9
9.2
23.1
2.3-139
CL-total
(ml/min)
26
38
20
231
27
139
20
51
56
65
13
34
9-286
CL-filter
(ml/min)
16
10
5
14
2
4
12
11
10
10
9
17
1-27
a
 Trimethoprim concentrations in haemofiltrate were below the limit of detection (<0.2 mg/1) in this patient.
bTherapy consisted of 1—3 different drugs in individual patients, resulting in a total of 37 treatment periods.
Dosage and administration
Antibiotics were administered intravenously either alone or in
combination (Table 1). The choice of antimicrobial therapy
for each patient was based on clinical judgement only. The
dosing interval was chosen according to the presumed half-
life of the respective drug.
Up to three different drugs were administered to each
patient during the study, resulting in a total of 37 evaluable
treatment periods. In many cases, several subsequent dosing
intervals per drug and patient were studied (64 totally) in
order to obtain more reliable data and to ensure that a
steady state was reached.
Specimen collection
Serial blood samples and pooled ultrafiltrate were obtained
at various time points during the steady state. On the average,
11 + 7 specimens were collected during each of the 37 treat-
ment periods. The optimal timing of sample collection was
determined individually depending on the drug to be stud-
ied and on the actual length of the dosing interval.
Concentrations of imipenem were determined immediately
due to its limited stability, while aminoglycoside and vanco-
mycin levels were assayed within 24 h. All other serum and
haemofiltrate samples were stored together with appropriate
control standards at — 70°C for up to 3 months before being
measured in batch.
Assay methods
Concentrations of beta-lactam antibiotics, ciprofloxacin, and
sulphamethoxazole were determined by HPLC whereas
the aminoglycosides and vancomycin were measured by a
fluorescence polarization immunoassay (Abbott TDX).
Pharmacokinetic analysis
The timing of the doses, dosing intervals, duration of infu-
sion, and the volume of the ultrafiltrate produced per time
unit were recorded for each patient. A serum concentration
versus time profile was plotted for each dosing interval and
the area under the curve (AUC) was calculated by the log-
trapezoidal method. The amount of drug excreted through
the haemofilter during one dosing interval was calculated
from the volume of collected ultrafiltrate and the drug
concentration in the ultrafiltrate. Standard model-inde-
pendent equations were applied to calculate
total body clearance (CL = Dose/AUC) and
filter clearance (excreted amount/AUC).
Selected drug properties such as protein binding (unbound
fraction fu), non-renal drug clearance fraction (Qo), and
normal clearance values (CLn) were derived from published
literature [6-8] (Table 2).
Statistical methods
The correlations of calculated and measured clearances were
determined by standardized principal component analysis
[9], and by distribution independent regression analysis
according to Passing and Bablok [10,11]. The latter model
estimates confidence intervals for slope and intercept and
tests for linearity by cusum statistics and by the run test.
The performance of the prediction method was determined
Table 2. Selected drug properties used to predict total body clearance
and haemofilter clearance [6—8]
Drug
Amikacin
Amoxycillin
Ceftazidime
Ciprofloxacin
Flucloxacillin
Imipenem
Netilmicin
Penicillin-G
Piperacillin
Sulphamethoxazole
Tobramycin
Vancomycin
Range
0.96
0.87
0.85
0.7
0.2
0.75
0.96
0.6
0.84
0.6
1.0
0.9
0.2-1.0
Qo8
0.02
0.06
0.05
0.5
0.3
0.3
0.01
0.08
0.25
0.8
0.02
0.05
0.01-0.8
(ml/min)
92
372
132
500
83
233
92
500
182
26
77
77
26-500
afu, unbound fraction; Qo, non-renal drug clearance fraction; CLn
normal clearance.
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by calculating bias and precision (root of mean squared
differences) according to Sheiner and Beal [12].
Results
Twenty-four patients were included in the study.
Approximately 50% of the patients experienced an
acute renal failure due to various internal medical
causes, e.g. septic shock, pneumonia, ARDS, pancreat-
itis, hepatorenal syndrome. One-third of the patients
suffered from postoperative acute renal failure follow-
ing either renal transplantation, combined renal and
pancreas transplantation, or cardiac surgery. The
remaining patients had multiple traumatic lesions or
traumatic brain injury. Half of the patients were on
the internal and half on the surgical intensive care
unit. All patients were attended by a nephrologist.
The antimicrobial therapy used consisted of 12
different antimicrobial agents given in a wide variety
of dosages either alone or in combination (Table 1).
Serum and nitrate kinetics were studied during a
total of 37 treatments (64 dosing intervals). The aver-
age ultrafiltrate flow rate was 13.2 ±4.6 ml/min
(mean + SD, range 3.2-22.1).
Using the fundamental pharmacokinetic drug para-
meters observed in individuals without renal failure
(Table 2), a theoretical model was derived which could
be used to predict the clearance values. The measured
haemofilter clearances and total body clearances
were in good agreement with fu-UFR and with
fu • UFR + Qo • Cln respectively. Figures 1 and 2 illus-
trate the distribution of the observed values. The
quantity fu • UFR was a good predictor of filter clear-
ance (Table 3). The majority of the measurements
deviated by less than 15%. Total body clearance was
underestimated by fu • UFR + Qo • Cln by an average of
7.6 ml/min. Deviations were <33%, however, in the
majority of the 37 treatment periods.
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Fig. 2. Measured and calculated total body clearance rates of 12
different drugs during continuous venovenous haemofiltration (calcu-
lated values were obtained from fu-UFR + Q0-CLn).
Table 3. Comparison of measured and calculated haemofilter clear-
ance and total body clearance values during 37 treatment periods
Method Filter clearance"
Predictive performance [12]:
bias (ml/min)
precision (rmseb)
0.6 (-0.2, 1.4)
2.4(1.7, 3.0)
Standardized principal component analysis [9]:
slope
y-intercept (ml/min)
0.94
1.3
Distribution-independent regression analysis [10,
slope0
y-interceptc (ml/min)
1.04(0.87, 1.24)
0.56 (-1.3, 2.0)
Total clearance8
-7.6 (-16.4, 1.1)
27.0(14.0, 35.6)
1.03
-8.9
1 ]:
0.81 (0.57, 1.05)
-2.0 (-9.9, 5.7)
Fig. 1. Measured and calculated haemofilter clearance rates of 12
different drugs during continuous venovenous haemofiltration (calcu-
lated values were obtained from fu-UFR).
* 95% confidence intervals are indicated in parentheses.
b
 Root of mean squared prediction error.
cNo statistically significant differences of slopes from 1 or of
intercepts from 0 (P<0.05) and no significant deviation from
linearity as determined by the cusum and run tests (P>0.1).
Comparison of the measured and calculated values
for both haemofilter and total body clearance by
distribution-independent linear regression analysis
yielded slopes of approximately 1 and y-intercepts near
0 ml/min (Table 3). No significant deviation from lin-
earity was found by the cusum and run tests (P>0.\).
Discussion
The existing mathematical models used to estimate
drug elimination during continuous renal replacement
therapy have recently been reviewed by Reetze-
Bonorden et al. [5]. Sieving coefficients are frequently
used to characterize the ability of a drug to pass
through the haemofilter membrane. These values, how-
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ever, have not been measured for all drugs used in
patients with acute renal failure.
The approach presented in this study has the advant-
age that all parameters needed to estimate drug clear-
ance are readily available. The convective transport
from blood to ultrafiltrate was calculated from ultrafil-
trate flow rate and unbound fraction alone, and the
non-renal clearance was assumed to be the same as in
patients without renal impairment. This simple model
is far from being perfect. It is evident that protein
binding may be altered in anuric patients and non-
renal elimination may be impaired in these severely ill
patients. Moreover, possible interactions due to mul-
tiple drug therapy may be responsible for pharmaco-
kinetic alterations. It is conceivable also that a reduced
hepatic clearance may be in part compensated by lower
protein binding and consequently increased haemofilter
clearance and vice versa.
Various statistical methods were used to compare
predicted with measured haemofilter and total body
clearances. Evaluation of predictive performance [12]
has become usual practice; however, this method
demands an independent variable presumed to be free
of experimental error. Standardized principal compon-
ent analysis [9] is a multivariate procedure, but normal
distribution of the values is required. Regression ana-
lysis, according to Passing and Bablok [10,11], may
overcome these drawbacks since it does not depend on
an error-free variable or on rigid distributional require-
ments. In addition, this procedure tests for a linear
relationship between the two variables, confidence
limits are given for the slope and the intercept, and
the influence of outliers is minimized.
The 12 drugs studied exhibited marked differences
in their protein binding as well as in their non-renal
contribution to total clearance. In addition wide ranges
of dose, dosing intervals, and ultrafiltration rates were
covered. Nevertheless in most patients the proposed
formula fu • UFR + Qo • CLn provided a reliable estimate
of the total drug clearance. The individual dosage
requirements may be calculated in proportion to the
ratio of total body clearance observed during CVVH
and the normal clearance rate found in patients without
renal impairment. Consequently the following formula
may be used to predict the maintenance dose during
renal replacement therapy.
Dose = Dn-(Q0 + fu-UFR/CLn)
where Dn denotes normal dose, CLn normal clearance,Qo non-renal clearance fraction, fu unbound fraction,
and UFR ultrafiltrate flow rate.
In conclusion, the results of the present study allow
practical dosage recommendations to be made for
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anuric patients undergoing CWH. Most drugs used
in clinical practice have relatively low molecular
weights, so that similar mechanisms of clearance during
CWH would be expected. It is therefore anticipated
that the same dosage calculations will also be appro-
priate for the majority of other therapeutic agents.
Monitoring serum concentrations, however, remains
mandatory when using drugs which possess a narrow
therapeutic range. Prospective studies are needed to
evaluate the efficiency of these dosage guidelines and
to study specifically whether the desired drug concen-
trations are achieved.
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